



U.S. Fish & Wildlife Service

The Aquatic Animal Drug Approval Partnership Program

Fact Sheet: LHRHa INAD 8061

INAD objective/purpose:	Collect supportive and pivotal data needed to establish the effectiveness of LHRHa to induce gamete maturation in a variety of fish species.
Drug name:	Luteinizing-Hormone-Releasing Hormone analogue – LHRHa
Source of drug:	Western Chemical, Inc.
Address:	1269 Lattimore Road Ferndale, WA 98248 USA
Contact:	Jason Montgomery Phone: 800-283-5292; Fax: 360-384-0270 email: jasonm@wchemical.com website: http://www.wchemical.com
Target pathogen(s):	Not Applicable
Method of administration:	IM or IP injection only, implants not permitted
Treatment dosage:	5 - 100 microgram (μ g) LHRHa per kilogram (kg) body weight
Treatment regimen:	Single or multiple treatment. Multiple treatment will generally consist of a single "priming dose," followed by a single "resolving dose." Administered IP or IM.
Withdrawal period:	14 days for all fish; no withdrawal period is required for injected fish that will not be susceptible to legal harvest for at least 14 days post-treatment.
Required test parameters:	Investigator must collect data reporting percent ovulation and/or percent spermiation in treated fish. Investigator should also report general fish behavior and any adverse effects relating to treatment.
Limitations or restrictions on use of drug:	Investigator must follow all instructions in the Study Protocol for INAD 8061 regarding drug acquisition and handling, fish treatment and disposition, and data reporting requirements. Use of LHRHa implants is not authorized Drug discharge must be in compliance with local NPDES permitting requirements.
Required INAD fee:	\$700.00/facility/year
AADAP Contact Information:	Ms. Bonnie Johnson, FWS-AADAP Phone: 406-994-9905 Fax: 406-582-0242 email: bonnie_johnson@fws.gov